Purposes The preoperative distinction between atypical meningioma (AM) and intracranial solitary fibrous tumor (SFT) holds significant importance in guiding surgical approach decisions and prognostic assessments. Methods A total of 310 SFT patients and 203 AM patients were retrospectively included and stratified into training and validation cohorts. Employing the elastic net algorithm, relevant features were identified to form the fusion radiomic model. Subsequently, a clinical-radiomic combined model was developed by integrating the fusion radiomic model with significant clinical variables through multivariate logistic regression analysis. The models’ calibration, discriminative capacity, and clinical utility were thoroughly assessed. Results The fusion radiomic model was crafted from 17 radiomic features, achieving AUC values of 0.920 in the training set and 0.870 in the validation set. Subsequently, the clinical-radiomic combined model exhibited AUC values of 0.930 and 0.890 in the training and validation sets, indicating commendable discrimination and calibration. Assessment through decision curve analysis underscored the clinical utility of both the fusion radiomic model and the clinical-radiomic combined model for individuals with intracranial SFT and AM. Conclusions The clinical-radiomic combined model exhibited notable sensitivity and exceptional efficacy in the distinctive diagnosis of intracranial SFT and AM, holding promise for the non-invasive advancement of personalized diagnostic and therapeutic strategies.
Background. Long noncoding RNA gastric cancer highly expressed transcript 1 (lncRNA GHET1) is often reported to be abnormally expressed in multiple cancers, but the situation is different in different cancers. Therefore, a meta-analysis is necessary to clarify the value of lncRNA GHET1 as a prognostic indicator in cancer. Methods. Relevant research studies on lncRNA GHET1 and cancer were retrieved from three electronic literature databases of Web of Science, PubMed, and OVID. Meanwhile, hazard ratios (HRs) and 95% confidence intervals (CIs) were calculated to explore the relationship between lncRNA GHET1 expression and survival of cancer patients. The odds ratios (ORs) and 95% CIs were calculated to assess the association of lncRNA GHET1 expression with pathological parameters of cancer patients. Results. The meta-analysis included a total of 11 studies involving 714 cancer patients. The pooled HR suggests that high lncRNA GHET1 expression is associated with poor overall survival. In addition, high expression of lncRNA GHET1 was found to be associated with larger tumor size, poor histological grade, high tumor stage, lymph node metastasis, and distant metastasis. Conclusions. High lncRNA GHET1 expression can predict poor survival and pathological parameters. And lncRNA GHET1 could serve as a new indicator in multiple cancers.